六月 2026
- Home
- Chimerix
六月 2026的Chimerix市场份额分析
At Chimerix, we are committed to developing medicines to meaningfully improve the probability of survival for people facing deadly diseases. By taking a differentiated approach to addressing difficult-to-treat diseases, we are accelerating the delivery of better treatments to make a bigger impact and rewrite the odds for patients.
Chimerix(包含公司地区分支机构)
查看更多网站流量和参与度信息- chimerix.com
Chimerix收入截至 六月 2026为 2M - 5M
Chimerix主要域名产生的收入
3 年中Chimerix主要域名的收入
Chimerix主要域名的收入
Chimerix热门域名的总访问量
了解Chimerix市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Chimerix热门域名的平均访问时长
分析Chimerix参与度指标。
过去 3 个月的平均访问时长
无数据可显示
无数据可显示
Chimerix热门域名的平均页面浏览量
了解Chimerix如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Chimerix 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Jazz Pharmaceuticals plc acquired Chimerix Inc. for $935M on Apr 21st '25.DUBLIN, April 21, 2025 /PRNewswire/ - Jazz Pharmaceuticals plc ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash.
四月 21, 2025阅读更多
新闻Jazz Pharmaceuticals, Inc. acquires Chimerix Inc. for $935M.Jazz Pharmaceuticals has completed the acquisition of Chimerix, Inc. for $935 million, adding a potential therapy for H3 K27M-mutant diffuse glioma to its oncology portfolio.
四月 21, 2025阅读更多
新闻Chimerix Inc. attended event JonesTrading Virtual Precision Medicine Symposium on Jan 29th '25.DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) - Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.
一月 29, 2025阅读更多
查看 Chimerix 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
